- Home
- XENE
as 10-29-2025 9:33am EST
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
Upcoming Earnings Alert:
Get ready for potential market movements as Xenon Pharmaceuticals Inc. XENE prepares to release earnings report on 03 Nov 2025.
| Founded: | 1996 | Country: | Canada |
| Employees: | N/A | City: | BURNABY |
| Market Cap: | 2.9B | IPO Year: | 2014 |
| Target Price: | $53.00 | AVG Volume (30 days): | 791.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.54 | EPS Growth: | N/A |
| 52 Week Low/High: | $26.74 - $46.00 | Next Earning Date: | 11-03-2025 |
| Revenue: | $7,500,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 207.88% |
Stock Insider Trading Activity of Xenon Pharmaceuticals Inc. (XENE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| MORTIMER IAN | XENE | PRESIDENT, CEO & INTERIM CFO | Oct 1 '25 | Sell | $40.16 | 25,000 | $1,004,000.00 | 31,302 |
Latest Xenon Pharmaceuticals Inc. News
XENE Breaking Stock News: Dive into XENE Ticker-Specific Updates for Smart Investing
MT Newswires
a month ago
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Thursday Amid Tech, AI Strength
MT Newswires
a month ago
Xenon Pharmaceuticals Insider Sold Shares Worth $1,004,000, According to a Recent SEC Filing
GlobeNewswire
2 months ago
Design Therapeutics Appoints Justin Gover to Board of Directors
Zacks
2 months ago
Why Is Xenon Pharmaceuticals (XENE) Up 4.2% Since Last Earnings Report?
Simply Wall St.
2 months ago
Did Higher-Than-Expected Losses Just Shift Xenon Pharmaceuticals' (XENE) Investment Narrative?
Simply Wall St.
2 months ago
An Intrinsic Calculation For Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Suggests It's 44% Undervalued
GlobeNewswire
4 months ago
Xenon Announces Appointment of Darren Cline as Chief Commercial Officer
MT Newswires
5 months ago
RBC Raises Price Target on Xenon Pharmaceuticals to $57 From $55, Keeps Outperform, Speculative Risk
Compare XENE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "XENE Xenon Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.